Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ProQR Therapeutics N.V (PRQR) EBT: 2021-2025

Historic EBT for ProQR Therapeutics N.V (PRQR) over the last 5 years, with Sep 2025 value amounting to -$12.9 million.

  • ProQR Therapeutics N.V's EBT fell 44.50% to -$12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$47.2 million, marking a year-over-year decrease of 79.87%. This contributed to the annual value of -$29.9 million for FY2024, which is 0.69% up from last year.
  • As of Q3 2025, ProQR Therapeutics N.V's EBT stood at -$12.9 million, which was up 6.53% from -$13.8 million recorded in Q2 2025.
  • ProQR Therapeutics N.V's EBT's 5-year high stood at -$3.1 million during Q2 2024, with a 5-year trough of -$23.4 million in Q3 2022.
  • Its 3-year average for EBT is -$8.9 million, with a median of -$8.9 million in 2024.
  • Its EBT has fluctuated over the past 5 years, first spiked by 74.62% in 2023, then slumped by 342.01% in 2025.
  • Over the past 5 years, ProQR Therapeutics N.V's EBT (Quarterly) stood at -$20.8 million in 2021, then surged by 34.89% to -$13.6 million in 2022, then soared by 56.56% to -$5.9 million in 2023, then tumbled by 68.70% to -$9.9 million in 2024, then slumped by 44.50% to -$12.9 million in 2025.
  • Its EBT was -$12.9 million in Q3 2025, compared to -$13.8 million in Q2 2025 and -$10.6 million in Q1 2025.